 Checkpoint Therapeutics, Inc. Checkpoint CKPT, a clinical-stage immunotherapy and targeted oncology company, today announced the pricing of its previously announced underwritten public offering. Checkpoint is offering 13,400,000 shares of its common stock, par value 0.0001 per share, at a price to the public of 1.27 per share. In connection with the offering, Checkpoint has also granted the underwriters a 45-day option to purchase up to an additional 2,010,000 shares of common stock offered in the public offering, at the same public offering price per share, less underwriting discounts and commissions. 